This narrative review by an expert International Osteoporosis Foundation (IOF) Working Group highlights an under-recognized bone health risk in women with early-stage, hormone receptor–positive breast ...

Step by step, little by little, we are learning how to act on this new staging information,’ one investigator says.

Metastasis-directed therapy for oligometastatic prostate cancer was associated with improved outcomes in a systematic review and meta-analysis.

Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...

Rheumatologist Dr Thomas Batty and haematologist Dr Emma Conway O'Brien describe a rational approach to investigating multifocal pain ...

Background and objectives Bone marrow metastasis (BMM) from non-hematolymphoid malignancies with resultant cytopenia(s) can ...

The FDA approved protocol updates to a tasquinimod trial in myelofibrosis, allowing broader enrollment and combination use ...

Hyderabad: Gland Pharma Limited, a generic injectable and ophthalmic-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for ...

In patients with metastatic breast cancer (mBC) who progress after first-line treatment of CDK4/6 and aromatase inhibitors (AI), the landscape of treatment options has expanded. Selective estrogen ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.

Detailed price information for Profound Medical Corp (PROF-Q) from The Globe and Mail including charting and trades.

Detailed price information for Profound Medical Corp (PRN-T) from The Globe and Mail including charting and trades.